Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icaritin Combined with Interventional Therapy for Advanced HCC in Child-Pugh B Patients
NCT06285149Phase 2Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Mar 2024
- Primary completion
- Dec 2024
- Modality
- Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 2 trial of Icaritin in hepatocellular carcinoma (HCC), sponsored by Henan Cancer Hospital. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
Icaritin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06285149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06285149.